CareDx Inc (CDNA) reported quarterly earnings results on Wednesday, Aug-10-2016. The company reported $-0.29 earnings per share for the quarter, missing the analyst consensus estimate by $-0.02. Analysts had a consensus of $-0.27. The company posted revenue of $10.70 million in the period, compared to analysts expectations of $10.42 million. The company’s revenue was up 50.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.27 EPS.
Many Wall Street Analysts have commented on CareDx Inc. Shares were Reiterated by Mizuho on Jun 14, 2016 to “Buy” and Lowered the Price Target to $ 8 from a previous price target of $12 .
CareDx Inc closed down -0.389 points or -7.80% at $4.601 with 26,206 shares getting traded on Monday. Post opening the session at $5, the shares hit an intraday low of $4.5934 and an intraday high of $5 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Jun 3, 2015, Peter Maag (CEO) purchased 2,000 shares at $4.84 per share price.
CareDx Inc. formerly XDx Inc. is a commercial-stage company which develops markets and delivers a diagnostic surveillance solution for heart transplant recipients. The Company’s commercialized testing solution the AlloMap heart transplant molecular test or AlloMap is a non-invasive blood-based test used to monitor heart transplant recipients for acute cellular rejection. AlloMap uses gene expression technology for the identification of heart transplant recipients. AlloMap provides a single integer score ranging from 0 to 40 and determines the probability of moderate to severe acute cellular rejection. As of December 31 2014 the Company performed more than 66000 commercial AlloMap tests in total. The Company is also engaged in the new product development in other areas of transplant surveillance such as the use of cell-free donor de-oxy ribonucleic acid (cfDNA) technology as a biomarker for rejection.